We also observed the opposite trend, where in one-third of tumors with cyclin D1 upregulation, cyclin D2 was downregulated, further supporting the hypothesis that genetic compensation in response to the perturbation of cyclin D function is a common phenomenon in HNSCC. This evidence concerns the gene CCND2 and head and neck squamous cell carcinoma.